BiotechTube

Famitinib + Ifosfamide + Camrelizumab

Phase 1/2Withdrawn
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Effect of Drugs

Conditions

Effect of Drugs, Progression, Pediatric Cancer

Trial Timeline

Aug 15, 2019 → Sep 30, 2022

NCT ID
NCT04044378

About Famitinib + Ifosfamide + Camrelizumab

Famitinib + Ifosfamide + Camrelizumab is a phase 1/2 stage product being developed by Jiangsu Hengrui Medicine for Effect of Drugs. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04044378. Target conditions include Effect of Drugs, Progression, Pediatric Cancer.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04044378Phase 1/2Withdrawn

Competing Products

20 competing products in Effect of Drugs

See all competitors
ProductCompanyStageHype Score
ORIN1001Fosun PharmaPhase 1/2
40
GP404141 + NplateGEROPHARMPhase 3
69
Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment CDaiichi SankyoPhase 1
33
E7386EisaiPhase 1
33
Duloxetine + WarfarinEli LillyPhase 1
33
Budesonide NasalJohnson & JohnsonApproved
85
SHR-1603Jiangsu Hengrui MedicinePhase 1
33
Apatinib+IE + IEJiangsu Hengrui MedicinePhase 2
52
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solutionAstraZenecaPhase 1
33
AZD6482 + Clopidogrel + ASAAstraZenecaPhase 1
33
Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + PlaceboAstraZenecaPhase 1
33
esomeprazole/ASA Fixed Dose Combination (FDC)AstraZenecaPhase 1
33
AZD6482 + PlaceboAstraZenecaPhase 1
33
MSC2156119JMerckPhase 1
33
Docetaxel + PembrolizumabMerckPhase 2
52
daptomycinMerckPhase 3
77
Cyclosporine & Cellcept + Prograf & Cellcept + Low Dose CNI (Cyclosporine or FK) and Cellcept + Rapamune and CellceptRochePhase 1/2
41
EvolocumabAmgenPhase 1
32
GS-0976 + PlaceboGilead SciencesPhase 1
32
Varenicline (Champix)PfizerPhase 1
32

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85